Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00798252 · ClinicalTrials.gov registry record · Phase 1
Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers
A Phase 1 study of Advanced Cancer, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 111
- Enrollment target
- 5
- Study locations
NCT00798252: Completed Phase 1 study of Advanced Cancer, sponsored by Bristol-Myers Squibb.
NCT00798252 is a Phase 1 study of Advanced Cancer that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 111 participants, below the 245-participant average among 122 other Advanced Cancer trials with a reported enrollment target (55% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00798252, a Phase 1 study of Advanced Cancer, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 111 participants
- Enrollment target
- 5
- Study locations
Study Summary
To determine safety and maximum tolerated dose of brivanib alaninate when administered in combination with capecitabine, doxorubicin, ixabepilone, docetaxel and paclitaxel chemotherapy to subjects with advanced or metastatic solid tumors
Conditions Studied
Interventions
- DRUG Docetaxel
- DRUG Capecitabine
- DRUG Doxorubicin
- DRUG Paclitaxel
- DRUG Ixabepilone
Study Locations (5)
California
- Usc/Norris Comprehensive Cancer Center - Los Angeles
Massachusetts
- Dana Farber Cancer Institute - Boston
Michigan
- Wayne State University - Detroit
Alberta
- Local Institution - Edmonton
Ontario
- Local Institution - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2009-03 |
| Est. Completion | 2015-05 |
| Phase | Phase 1 |
What the finished NCT00798252 record still lists
NCT00798252 is an interventional study that assigns participants to a tested intervention. The registered 111 participants enrollment target is mid-sized for trials with a published cap, below the 245-participant average among 122 other Advanced Cancer trials with a reported enrollment target (55% lower).
The record links to 1 condition, with Advanced Cancer appearing as the primary indexed condition, and to 5 interventions - of which Docetaxel is the first listed.
NCT00798252 lists 5 locations in 5 states (California, Massachusetts, Michigan).
Frequently Asked Questions
What is clinical trial NCT00798252 about?
NCT00798252 is a clinical study titled "Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers". To determine safety and maximum tolerated dose of brivanib alaninate when administered in combination with capecitabine, doxorubicin, ixabepilone, docetaxel and paclitaxel chemotherapy to subjects with advanced or metastatic solid tumors
What is the current status of trial NCT00798252?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 111 participants. The study started on 2009-03. Estimated completion is 2015-05.
What conditions does trial NCT00798252 study?
This clinical trial studies the following conditions: Advanced Cancer.
What interventions are being tested in trial NCT00798252?
The interventions under investigation include: Docetaxel (DRUG), Capecitabine (DRUG), Doxorubicin (DRUG), Paclitaxel (DRUG), Ixabepilone (DRUG).
Who is sponsoring clinical trial NCT00798252?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00798252 being conducted?
This trial has 5 study locations across California, Massachusetts, Michigan, Alberta, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00798252's enrollment target sits among peer trials
111 56th of 122 higher than 67 of 122 other Advanced Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss
RECRUITING · Phase 1
-
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study in Patients With Advanced Cancers
RECRUITING · Phase 1
-
A Study of MGC026 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03875716 · 111 participants · NA
Study of De_Intensified Postoperative Radiation Therapy for HPV Associated Oropharyngeal Squamous Cell Carcinoma
- NCT04693468 · 111 participants · Phase 1
Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial
- NCT05263050 · 111 participants · Phase 2
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
- NCT05600842 · 111 participants
De-escalated Radiation for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia